Edition:
India

Reata Receives Orphan Drug Designation From The European Commission For Omaveloxolone


Wednesday, 11 Jul 2018 

July 10 (Reuters) - Reata Pharmaceuticals Inc ::REATA RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR OMAVELOXOLONE FOR THE TREATMENT OF FRIEDREICH’S ATAXIA.REATA PHARMACEUTICALS - CURRENTLY ENROLLING ABOUT 100 FA PATIENTS IN REGISTRATIONAL PART 2 PORTION OF PHASE 2 TRIAL MOXIE, AND SEES RESULTS IN H2 2019. 

Company Quote

184.91
 --
18 Oct 2019